Articles On Orthocell (ASX:OCC)

Highlights Staples drag the index lower amid cost pressures Energy sector gains strength on rising oil momentum Lithium players stay resilient with upbeat sentiment The Australian market extended its losing streak as w...

ASX closes lower despite eight sectors finishing in the green Staples smashed as Woolies and Coles sold off sharply Lithium keeps climbing on stronger Chinese futures   It’s eight days straight of S&P/ASX 200 blood. The closing clang...

Orthocell reports first commercial sales of Remplir in Canada following regulatory approval and 2025 launch activities Distributor-led model supports national coverage and capital-light entry into ~US$75m Canadian market Remplir now genera...

Shares in small-cap biotech Orthocell (ASX: OCC) edged higher today (around 4% at the time of writing) after the company released a clinical update that could prove more important than the market initially realised. At the centre of t...

Adheris Health defies tricky US conditions, but investors say ‘meh’  Orthocell reports “compelling” Remplir real world evidence LTR progresses its erection spray while Acrux targets women’s sexual health   Ahead of Thursday’s end-of-month...

Remplir real-world evidence study shows 89.7% treatment success across 66 patients and 78 procedures Strong outcomes in both motor nerve repair (90.3%) and nerve decompression (89.4%), with no reported safety issues Data to support continu...

ASX closed down 0.04% after early dip, failing to fully follow through on some arvo promise Energy dropped almost 1%, making it the worst sector as oil tension weighs Tech on a six-day streak while Rio held firm; broader market stalled  ...

Host Tylah Tully sits down with Orthocell (ASX:OCC) Managing Director and CEO Paul Anderson to discuss Orthocells growing traction in the US market, delivering strong revenue growth with expansion across key hospital networks. Anderson high...

Orthocell Ltd (ASX: OCC) shares are in focus today after its share price tumbled 7% to start the week of trading on Monday.  This came following the company's Quarterly Activity Report.  Orthocell is a regenerative medicine company. T...

ASX All Ords gold stock Aurum Resources Ltd (ASX: AUE) has delivered some outsized gains this past year. Aurum Resources shares closed on Monday trading for 64 cents apiece. That sees shares in the African-focused gold miner up 67% in 12 mo...

Valuations often build up before the FDA decision EMVision edges toward a De Novo inflection ASX medtech winners show what approval unlocks   There’s a moment in healthcare investing that tends to separate the early conviction money from...

A major US cancer research pow-wow includes ‘poster’ presentations from Radiopharm Theranostics and Arovella Therapeutics Syntara’s myelofibrosis drug candidate wins backing from an unlikely source Orthocell closes in on quarterly breakeve...

Perth-based regenerative medicine company Orthocell Limited (ASX: OCC) has secured approval for its Remplir nerve repair device across the United States Department of Defense (DoD) and Veterans Affairs (VA) hospital networks, opening access...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Orthocell receives approval for Remplir™ to be used across the United States Depart...

ASX crawls just 0.09% higher Financials gives up gains, unwinding market momentum Energy, utilities drag as US-Iran ceasefire continues Market struggles to hold momentum It was relatively quiet on the Middle Eastern front, with no dramati...

ASX small cap stock Orthocell Ltd (ASX: OCC) delivered a standout performance today, with shares surging 22% (at the time of writing) after the company announced a major commercial milestone in the United States. What did the company ann...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully looks at Orthocell’s (ASX:OCC) new commercial breakthrough as it unlocks Remplir approval across the US Department of De...

Orthocell shares soar 20% after the go-ahead to sell flagship Remplir product to US defence and vet affairs hospitals Telix seals monster $840 million debt capital raising Forget Lego – Genetic Signatures finds its own Danish building bloc...

Investors with a high tolerance for risk might want to check out the exciting small-cap ASX stock in this article. That's because the team at Bell Potter has just initiated coverage on it with a bullish view. Which small-cap ASX stock? The...

ASX overcomes early jitters to climb 0.31% Broad strength across 10 sectors with 127/200 stock rising Info tech, energy and travel stocks power gains Oil dips on Iraq-Kurdistan export deal A marginal (-2.4%) retreat in oil prices to just...

Orthocell’s Remplir used in 23 surgical procedures in Ukraine on soldiers who sustained nerve injuries during combat Flagship nerve repair product designed to connect, protect and cap severed nerves resulting from trauma Surgeons in the re...

Orthocell Ltd (ASX: OCC) shares are catching the eye on Wednesday morning. In early trade, the ASX All Ords stock is up 5% to 82 cents. Why are Orthocell shares rising today? The company's shares are pushing higher today following the relea...

Highlights Market scans highlight strong upward momentum and persistent downward pressure across several ASX-listed companies Technology, resources and retail stocks dominate the latest trend shifts Chart-based analysis cont...

ASX rises 1.09% with nine sectors higher Oil prices slide as US President Trump says Iran war is ‘very complete, pretty much’ Energy stocks give up gains, gold index leads market higher   Oil prices slide as Trump muddies Iran war waters...

Orthocell eyes US nerve repair market
 Less than 1% market share could reach breakeven
 Remplir begins early US sales momentum   In operating theatres across the United States, surgeons repair hundreds of thousands of damaged nerves every...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

Banks and tech stocks power ASX higher NAB hits record; Superloop and Netwealth rally on strong results Santos cuts workforce as wage growth trails inflation   The ASX extended its three-day winning streak on February 18, closing 0.53% hi...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets finished slightly down on Friday as the public debate around the next Fed...

ASX climbs 0.48% in strong performance Nine of 11 sectors higher with 133/200 stocks climbing Most metals rally in solid commodity gain   Market powers higher in final hour The ASX 200 had a steady day of trade firmly above the line today...

Orthocell books a record quarterly revenue of $3.2 million for December quarter Revenue increased 7% in December compared to previous quarter and 45.2% over the pcp Seventh consecutive quarter of growth, achieving 10.4% compound quarterly...

Tylah Tully looks at the advancements Orthocell (ASX:OCC) have made over the past year and ahead to a 2026 which promises to have a scaling of its leading nerve repair treatment across the United States and more international markets.     T...

Highlights Janus Electric gains traction after key approval Mixed trading mood across broader market Company updates drive sector-specific interest The broader market eased while select companies drew attention through...

Orthocell Ltd (ASX: OCC) shares are having a good session on Tuesday. In morning trade, the small cap ASX share has risen 3% to $1.13. Why is this small cap ASX share charging higher? Investors have been buying the regenerative medicine com...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

Several ASX healthcare names secured US Food and Drug Administration approval in 2025, opening up the world’s largest healthcare market PainChek’s Adult App became first regulated device to assess pain in people who can’t reliably verbalis...

Highlights Resource updates signal growing project confidence Approvals and funding steps reshape development timelines Small-cap activity adds depth to local market sentiment Australian small-cap companies are advanci...

Orthocell submits application for approval of flagship nerve repair product Remplir in the UK and EU With ~500,000 surgical repairs of peripheral nerves annually in the region, market represents US$750 million opportunity Supported by real...

ASX trades sideways ahead of US Fed decision overnight Eight of 11 sectors down, weak breadth with 121/200 stocks falling Materials sector propped up by gold and silver prices   ASX trades sideways The ASX 200 is still in wait-and-see mod...

Orthocell achieves first commercial sales of Remplir in Hong Kong Sales mark a key milestone in Orthocell’s Asian growth strategy Remplir now selling in five major markets with two more expected in near term   Special Report: Orthocell ha...

Cogstate shares plunge on revenue and earnings downgrade Immuron shares have the runs after failed US military trial Was Immutep’s share price reaction underdone?   CogState (ASX:CGS) shares have tumbled as much as 30% on the back of a r...

Orthocell Ltd (ASX: OCC) shares are having a strong session on Wednesday. In morning trade, the ASX healthcare stock is up 7% to $1.09. Why is this ASX healthcare stock jumping? Investors have been buying the regenerative medicine company's...

John Van Der Wielen succeeds Neale Fong and adds to his chairmanships of the ASX-listed biotech Orthocell and the WA Government’s Future Health and Research Fund. 

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Host Tylah Tully chats with Orthocell (ASX:OCC) managing director and CEO Paul Anderson about the growing momentum behind Remplir, as surgeons find  a new indication for the company’s lead product. Most recently, the device has been adopted...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Company to invest in further research to strengthen clinical evidence ahead of mediu...

Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from...

Orthocell (ASX:OCC) has seen its share price jump on Thursday as the company unveils its latest early-stage successes observed in Australian prostate surgery patients who use nerve repair product Remplir. Listen to the HotCopper podcast...